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Davide Capodanno, MD, PHD,* Corrado Tamburino, MD, PHD*xABSTRACTFro
of
anOBJECTIVES The purpose of this study was to investigate the effect of the RenalGuard System (PLC Medical Systems,
Milford, Massachusetts) on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve
replacement (TAVR).
BACKGROUND TAVR is associated with varying degrees of post-procedural AKI. The RenalGuard System is a dedicated
device designed for contrast-induced AKI prevention. Whether this device is also effective in patients with severe aortic
stenosis undergoing TAVR is unexplored.
METHODS The present is an investigator-driven, single-center, prospective, open-label, registry-based randomized
study that used the TAVR institutional registry of the Ferrarotto Hospital in Catania, Italy, as the platform for random-
ization, data collection, and follow-up assessment. A total of 112 consecutive patients undergoing TAVR were randomly
assigned to hydration with normal saline solution controlled by the RenalGuard system and furosemide (RenalGuard
group) or normal saline solution (control group). The primary endpoint was the incidence of Valve Academic Research
Consortium–deﬁned AKI in the ﬁrst 72 h after the procedure.
RESULTS The AKI rate was lower in the RenalGuard group than in the control group (n ¼ 3 [5.4%] vs. n ¼14 [25.0%],
respectively, p ¼ 0.014). The majority of patients (5.4% vs. 23.2%) developed a mild AKI (stage 1); severe damage (stage 3)
occurred only in 1 patient in the control group (0.0% vs. 1.8%). No case of in-hospital renal failure requiring dialysis was
reported. No signiﬁcant differences in terms of mortality, cerebrovascular events, bleeding, and hospitalization for heart
failure were noted in both groups at 30 days.
CONCLUSIONS Furosemide-induced diuresis with matched isotonic intravenous hydration using the RenalGuard sys-
tem is an effective therapeutic tool to reduce the occurrence of AKI in patients undergoing TAVR. (J Am Coll Cardiol Intv
2015;8:1595–604) © 2015 by the American College of Cardiology Foundation.m the *Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; yDepartment of Cardiology, University
Tokai, School of Medicine, Isehara, Japan; zThe Valve & Structural Heart Disease Intervention Center, Harrington Heart
d Vascular Institute, University Hospitals, Case Medical Center, Cleveland, Ohio; and the xETNA Foundation, Catania, Italy.
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1596A cute kidney injury (AKI) is afrequent complication of contrast-guided interventional procedures
(1,2). Not surprisingly, transcatheter aortic
valve replacement (TAVR) is also associated
with varying degrees of post-procedural
AKI, ranging from 12% to 57%, which carries
a negative prognostic effect (3–8). Preventive
intravenous hydration with isotonic saline
solution is known to decrease the risk of
AKI (9,10). However, in patients withimpaired left ventricular function and left side
valvular heart diseases, hydration is usually subop-
timal due to the perceived risk of overhydration
and pulmonary edema. In previous studies, diuretic
agents have been combined with hydration to in-
crease urine output and prevent overhydration
(11–13).SEE PAGE 1605The RenalGuard System (PLC Medical Systems,
Milford, Massachusetts), a recently introduced de-
vice delivering intravenous ﬂuids matched to the
urine output, has emerged as an alternative strategy
for AKI prevention. Studies conducted in patients
undergoing percutaneous coronary intervention have
recently demonstrated that furosemide-induced
diuresis with matched isotonic intravenous hydra-
tion by the RenalGuard System signiﬁcantly reduced
AKI in high-risk patients undergoing coronary pro-
cedures (14–16). Whether these ﬁndings translate to
patients undergoing TAVR is unexplored. To ﬁll this
gap, we performed a randomized study to assess the
efﬁcacy of the RenalGuard System to prevent AKI
in patients with severe aortic stenosis undergoing
TAVR.
METHODS
STUDY DESIGN. PROTECT-TAVI (PROphylactic effecT
of furosEmide-induCed diuresis with matched iso-
tonic intravenous hydraTion in Transcatheter Aortic
Valve Implantation) was an investigator-driven, sin-
gle-center, prospective, open-label, registry-based
randomized study that used the TAVR institutional
registry of the Ferrarotto Hospital in Catania, Italy
(REPLACE [REgistry of Percutaneous aortic vaLve
replacement]), as the platform for randomization,i has served as a consultant and proctor to Medtronic and Edwar
al. All other authors have reported that they have no relationshi
ti and Gulino contributed equally to this work.
received May 25, 2015; revised manuscript received July 9, 2015data collection, and follow-up assessment. All trial
management activities including data management
and statistical analyses were performed at the Ferrar-
otto Hospital, Catania. All subjects provided written
informed consent before randomization. The study
was conducted according to the principles of the
Declaration of Helsinki and Good Clinical Practice.
The authors wrote all drafts of the paper and vouch
for the integrity of and completeness of the data and
analyses.
THE REPLACE REGISTRY. REPLACE is a spontaneous
registry created to monitor the institutional proce-
dural, acute, and long-term outcomes of TAVR. A
stream of patient demographics, medical history,
concomitant medications, procedure details, and in-
hospital clinical outcomes is routinely entered in the
registry’s electronic data collection system using
standardized case report forms. Follow-up data are
obtained at serial time points by clinical visits and
phone calls. Trial-speciﬁc information, including
renal outcomes of interest not obtained as part of the
registry, was collected using additional case report
form pages.
STUDY POPULATION. All consecutive patients with
symptomatic severe aortic stenosis undergoing TAVI
were considered eligible for the trial. Exclusion criteria
included chronic end-stage renal failure on dialysis,$1
episode of acute congestive heart failure with left
ventricular ejection fraction <30% in the past 30 days
before randomization, contraindications to placement
of a Foley catheter, urgent TAVI, and unavailability of
the RenalGuard system before randomization. All an-
alyses were performed following the intention-to-
treat principle.
RANDOMIZATION. Patients were 1:1 randomly
assigned to either RenalGuard or standard manage-
ment. Randomization was obtained with computer-
generated codes, which were sealed in sequentially
numbered envelopes.
STUDY PROCEDURES. Study procedures are detailed
in the Central Illustration. The iodixanol (Visipaque, GE
Healthcare, Little Chalfont, Buckinghamshire, United
Kingdom), a nonionic, iso-osmolar (290 mOsm/1 kg
water) contrast agent was used during TAVR in
all patients. Patients randomized to RenalGuard
received hydration with a normal saline solution. Theds Lifesciences; and has served as a consultant to St.
ps relevant to the contents of this paper to disclose.
, accepted July 16, 2015.
CENTRAL ILLUSTRATION Study Protocol
i.v. ¼ intravenous; TAVI ¼ transcatheter aortic valve implantation.
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1597RenalGuard system (Figure 1) includes a closed-loop
ﬂuid management system, a high-volume ﬂuid pump,
a high-accuracy dual weight measuring system,
motion-detection artifact reduction, a single-use
intravenous set and urine collection system that in-
terfaces with a standard Foley catheter, real-time
display of urine and replacement ﬂuid volume,
timely alerts to drain the urine bag or to replace the
hydration ﬂuid bag, and safety features such as auto-
matic air and occlusion detection. An initial bolus
(priming) of 250 ml was infused over 30 min (pre-
procedural phase). In the presence of left ventricular
dysfunction (ejection fraction <30% as assessed by
2-dimensional echocardiography), priming was re-
duced to 150 ml. After the priming, furosemide(0.25 mg/kg) is administered intravenously to achieve
an optimal urineﬂowof>300ml/h. As soon as the urine
ﬂow reached the target value, the patient was moved
into the catheterization laboratory and the TAVR
procedure was started (procedural phase). Controlled
hydration by the RenalGuard system continued during
the procedure and for 4 h after the procedure (post-
procedural phase). Urine ﬂow was monitored and
maintained at the target value throughout the proce-
dure and during the following 4 h. Additional furose-
mide doses were allowed in instances when therewas a
decrease in urine ﬂow below the target value.
Patients allocated to the control group received
sodium normal saline solution at a rate of 1 ml/kg/h
12 h before TAVR, during contrast exposure, and for
FIGURE 1 RenalGuard System
Schematic representation of the RenalGuard system (PLC Medical Systems, Milford,
Massachusetts) connected to the patient. TAVR ¼ transcatheter aortic valve replacement.
FIGURE 2 Study Flow Chart
A total of 112 patients were randomized and assigned to either the Renal
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15986 h after the procedure. In the presence of left ven-
tricular dysfunction (ejection fraction <30% as
assessed by 2-dimensional echocardiography), the
hydration’s rate was reduced to 0.5 ml/kg.
ENDPOINTS AND DEFINITIONS. The primary end-
point was the incidence of AKI occurring within the
ﬁrst 72 h after the procedure. Secondary outcomes
were deﬁned according to the Valve Academic Re-
search Consortium (VARC) (17).
AKI was deﬁned as an absolute reduction in kidney
function (#72 h) and deﬁned as: 1) stage 1: increase in
serum creatinine to 150% to 200% (1.5 to 2.0 in-
crease compared with baseline) or increase of $0.3
mg/dl ($26.4 mmol/l); 2) stage 2: increase in serum
creatinine to 200% to 300% (2.0 to 3.0 increase
compared with baseline); and 3) stage 3: increase in
serum creatinine to $300% (>3 increase compared
with baseline) or serum creatinine of $4.0 mg/dl
($354 mmol/l) with an acute increase of at least 0.5
mg/dl (44 mmol/l).
Estimates of glomerular ﬁltration rate were
calculated by applying both the Cockcroft-Gault and
the Modiﬁcation of Diet in Renal Disease formulas.
A risk score for predicting contrast-induced AKI
was calculated as previously described by Mehran
et al. (18).
SERUM BIOMARKERS. Serum creatinine, blood urea
nitrogen, sodium, and potassium were measured the
day before the procedure; at 24, 48, and 72 h afterGuard group (n = 56) or the control group (n = 56) with no crossover.
TABLE 1 Baseline Characteristics
RenalGuard Group
(n ¼ 56)
Control Group
(n ¼ 56) p Value
Clinical parameters
Age, yrs 82 (78–83) 81 (78–84) 0.908
BMI, kg/m2 26  4.7 28  4.6 0.143
Female 34 (60.7) 33 (58.9) 0.847
Hypertension 42 (75.0) 49 (87.5) 0.145
Diabetes mellitus 16 (28.6) 22 (39.3) 0.318
Dyslipidemia 27 (48.2) 30 (53.6) 0.706
Prior acute heart failure† 18 (32.1) 14 (25.0) 0.531
Prior myocardial infarction 4 (7.1) 6 (10.7) 0.742
Prior stroke/TIA 5 (8.9) 2 (3.6) 0.438
Prior bypass graft surgery 3 (5.4) 6 (10.7) 0.489
Prior PCI 9 (16.1) 9 (16.1) 0.603
Prior aortic valvuloplasty 2 (3.6) 1 (1.8) 0.569
Peripheral vascular disease 8 (14.3) 9 (16.1) 0.798
Chronic obstructive pulmonary disease 12 (21.4) 9 (16.1) 0.629
Prior pacemaker 5 (8.9) 7 (12.5) 0.761
Porcelain aorta 1 (1.8) 1 (1.8) 0.752
NYHA functional class III and IV 46 (82.1) 46 (82.1) 0.517
Serum creatinine, mg/dl 1.0 (0.85–1.15) 0.97 (0.83–1.16) 0.357
eGFR, mg/dl* 50.0  20.7 53.0  19.2 0.488
eGFR,† mg/dl 62.6  25.6 63.5  20.6 0.848
eGFR* #30 mg/dl 9 (16.1) 6 (10.7) 0.580
eGFR† #30 mg/dl 5 (8.9) 3 (5.4) 0.716
eGFR* between 30 and 60 mg/dl 29 (50) 30 (53.6) 0.850
eGFR† between 30 and 60 mg/dl 22 (39.3) 20 (35.7) 0.845
STS score 4.5 (4.0–5.0) 3.8 (2.8–4.8) 0.761
Medications at time of randomization
Aspirin 30 (53.6) 25 (44.6) 0.848
ARB 23 (41.1) 23 (41.1) 0.935
ACE inhibitors 13 (23.2) 14 (25.0) 0.825
Furosemide 35 (62.5) 38 (67.8) 0.545
Baseline echocardiographic parameters
LVEF, % 53.6  13 55.5  8.7 0.356
Peak pressure gradient, mm Hg 85.0  21.5 80.4  18 0.230
Mean pressure gradient, mm Hg 53.0  15.4 48.0  11.5 0.066
Aortic valve area, cm2 0.6  1.7 0.7  1.7 0.084
Values are median (interquartile range), mean  SD, or n (%). *Cockcroft-Gault formula. †Modiﬁcation of Diet in
Renal Disease formula.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; eGFR ¼
estimated glomerular ﬁltrate rate; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; STS ¼ Society of Thoracic Surgery; TIA ¼ transient ischemic attack.
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1599administration of the contrast agent; and before
discharge.
SAMPLE SIZE CALCULATION. Averaging the 12% and
57% AKI rates post-TAVR reported by the available
published data (4,5,19,20) and the AKI rate in the
REPLACE registry before trial initiation (30%), we
anticipated that the overall rate of AKI in the control
group would be 28%. Assuming an incidence of 8% of
overall rate of AKI in the RenalGuard group, a sample
size of 110 patients (55 patients per group) provided
80% power to detect statistically signiﬁcant differ-
ences in AKI at a 2-sided alpha of 0.05.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD or medians with ﬁrst (Q1)
and third (Q3) quartiles in cases of skewed distri-
butions. Categorical variables are described by fre-
quencies and percentages. Differences between
independent groups were tested using the Wilcoxon
rank sum test and Student t test for continuous
variables. In cases in which the samples were paired,
the Wilcoxon signed rank or paired Student t test
were used. Categorical variables were compared with
the chi-square test. Relative risks are reported with
95% conﬁdence intervals (CIs). A Pearson correlation
analysis was used for the evaluation of 2 continuous
variables.
A multivariable analysis for the development
of AKI was performed using a logistic regression,
adjusting for the following variables: “no RenalGuard
use” and AKI risk score 4. All tests were 2-tailed, and
a p value of 0.05 was required for statistical signiﬁ-
cance. All data were processed using the Statistical
Package for Social Sciences, version 20 (IBM, Armonk,
New York).
RESULTS
POPULATION. The ﬂow of the study is depicted in
Figure 2. Between February 2014 and January 2015,
118 patients were screened for TAVR. Six patients met
at least 1 exclusion criterion. A total of 112 patients
with a mean age of 80.6  5.1 years were randomized
and assigned to either the RenalGuard group (n ¼ 56)
or the control group (n ¼ 56). All patients received the
allocated AKI prevention protocol with no crossovers.
Follow-up data for the primary and secondary end-
points was available for all patients. Serum creati-
nine, sodium, and potassium values at baseline and
post-procedure were available for all patients in
each group.
Baseline demographic, clinical, and echocardio-
graphic characteristics of 2 study groups are summa-
rized in Table 1. An estimated glomerular ﬁltrationrate <60 ml/m calculated by the Cockcroft-Gault and
the Modiﬁcation of Diet in Renal Disease formulas
was reported in 74 patients (66.1%) and 50 patients
(44.6%), respectively. A total of 64 patients (57%)
had moderate predicted risk to develop a contrast-
induced AKI according to the Mehran risk score,
with no differences between study groups (Figure 3).
PROCEDURAL OUTCOMES. Procedural data are
shown in Table 2. VARC-deﬁned device success was
obtained in 107 patients (95.5%), with no differences
between the 2 groups. Also, no differences in terms of
contrast dye administered were observed.
FIGURE 3 AKI Risk Score
Predicted risk score to develop a contrast-induced acute kidney injury (AKI) according to Mehran et al. (18).
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1600PRIMARY ENDPOINT AND RENAL OUTCOMES. The
incidence of AKI was lower in the RenalGuard group
compared with the control group (n ¼ 4, 5.4% vs. n ¼
13, 25.2%; relative risk: 0.21 [95% CI: 0.06 to 0.71]; p ¼TABLE 2 Procedural Data
RenalGuard Group
(n ¼ 56)
Control Group
(n ¼ 56) p Value
Device success 55 (98.2) 52 (92.8) 0.170
Device
CoreValve, Medtronic 40 (71.4) 31 (55.3) 0.116
SAPIEN, Edwards 10 (17.8) 22 (39.3) 0.021
Portico, St. Jude 2 (3.6) 1 (1.8) 0.558
Lotus, Boston 2 (3.6) 1 (1.8) 0.558
Rapid pacing use 56 (100) 56 (100) 1.000
Concomitant PCI 6 (10.7) 5 (8.9) 0.751
Post-dilation 12 (21.4) 7 (12.5) 0.314
Valve-in-valve* 2 (3.6) 3 (5.3) 0.647
Valve-on-valve† 1 (1.8) 2 (3.6) 0.558
Contrast dye (ml) 180 (140–220) 170 (130–230) 0.633
Values are n (%) or median (interquartile range). *Valve-in-valve: implantation of
a second prosthesis inside the ﬁrst one to treat the ﬁrst valve’s malposition during
the index procedure. †Valve-on-valve: implantation of a second valve in its
anatomical position after embolization in ascending aorta of the ﬁrst valve
deployed.
PCI ¼ percutaneous coronary intervention.0.014). The majority of patients developed a mild AKI
(stage 1), whereas severe AKI (stage 3) occurred in
only 1 patient in the control group (Figure 4). No case
of in-hospital renal failure requiring dialysis was re-
ported. Key characteristics of patients who developed
AKI are listed in Table 3. A signiﬁcant increase inFIGURE 4 Study Primary Endpoint
Incidence of acute kidney injury (AKI) stages 1 and 3 in the study
population. CI ¼ conﬁdence interval; RR ¼ relative risk.
TABLE 3 Characteristics of Patients Who Developed AKI
n Group
Age
(yrs) Sex
LVEF
(%)
CI-AKI
Risk Score
Baseline eGFR
(CG/MDRD)
Minimum eGFR
(CG/MDRD)
Creatinine Peak
(mg/dl)
Contrast
Volume (ml) AKI Stage
1 Control 84 F 60 12.1 52.2/77.1 19.3/22.9 2.06 310 1
2 Control 85 F 60 16.0 28.2/36.5 17.5/19.8 2.34 100 1
3 Control 83 M 50 16.0 61.0/94.0 38.7/52.3 1.31 100 1
4 Control 74 F 60 4.7 63.2/65.1 46.6/43.1 1.22 170 1
5 Control 81 F 69 18.0 23.9/32.3 18.1/22.1 2.15 200 1
6 Control 67 F 33 1.0 91.7/75.2 60.9/44.1 1.22 100 1
7 Control 84 M 57 7.0 53.6/63.8 10.4/9.1 5.97 300 3
8 Control 83 M 48 14.2 69.4/78.6 35.8/34.4 1.88 220 1
9 Control 85 F 60 13.2 41.7/49.1 27.8/29.0 1.68 120 1
10 Control 74 F 48 17.0 38.1/30.0 26.8/18.8 2.50 200 1
11 Control 74 F 50 8.0 45.5/50.2 28.4/27.4 1.81 200 1
12 RG 73 M 50 17.5 45.0/33.2 30.5/19.9 3.10 250 1
13 RG 84 F 45 20.8 23.0/24.6 14.4/13.5 3.27 180 1
14 Control 81 F 35 16.2 29.9/38.4 23.2/27.0 1.80 120 1
15 Control 83 M 68 19.6 31.5/33.7 25.6/24.9 1.92 60 1
16 Control 83 F 60 17.9 36.2/57.6 16.4/21.7 2.80 290 1
17 RG 84 F 62 14.0 39.7/56.3 30.1/38.4 1.32 200 1
CG ¼ Cockcroft-Gault formula; CI-AKI ¼ contrast induced acute kidney injury; MDRD ¼ Modiﬁcation of Diet in Renal Disease formula; RG ¼ RenalGuard; other abbreviations
as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 2 , 2 0 1 5 Barbanti et al.
O C T O B E R 2 0 1 5 : 1 5 9 5 – 6 0 4 Acute Kidney Injury Prevention in TAVR
1601serum creatinine was noted in the control group
compared with the RenalGuard group (Figure 5).
Figure 6 shows the relationship between the vari-
ation in creatinine value and the amount of contrast
dye administered during the procedure in the
2 groups. This correlation was found to be signiﬁcant
in the control group (p ¼ 0.028) but not in the
RenalGuard group (p ¼ 0.570).FIGURE 5 Serum Biomarkers
Trends of serum creatinine (left), sodium (middle), and potassium (righSECONDARY OUTCOMES. No signiﬁcant hydration-
associated complications were observed. A total of 41
patients (23 patients [41.1%] in the RenalGuard group
vs. 18 patients [32.1%] in the control group; p ¼ 0.432)
developed asymptomatic hypokalemia that was
corrected with potassium supplementation as per
usual practice. No patients developed hypernatremia
(Figure 5). No cases of pulmonary edemawere reported.t) values. TAVI ¼ transcatheter aortic valve implantation.
FIGURE 6 Renal Function and Contrast Dye
Variation in creatinine value in response to contrast dye administered in the 2 groups.
TABLE 4 Clinical Outcomes Up to 30 Days
RenalGuard
Group (n ¼ 56)
Control
Group (n ¼ 56) p Value
In-hospital
Death 1 (1.8) 2 (3.6) 0.537
Cardiovascular death 0 (0) 1 (1.8) 0.306
Stroke/TIA 0 (0) 0 (0) —
Permanent PM 6 (10.7) 5 (8.9) 0.799
Bleeding 5 (8.9) 6 (10.7) 0.354
Life threatening 2 (3.6) 0 (0.0) 0.558
Major 1 (1.8) 3 (5.4) 0.309
Minor 2 (3.6) 3 (5.4) 0.647
Major vascular complication 3 (5.4) 3 (5.4) 0.661
Minor vascular complication 13 (23.2) 6 (10.7) 0.078
Acute kidney injury 3 (5.4) 14 (25.0) 0.014
Stage 1 3 (5.4) 13 (23.2) 0.013
Stage 2 0 (0.0) 0 (0.0) —
Stage 3 0 (0.0) 1 (1.8) 0.315
30 days
Death 1 (1.8) 1 (1.8) 0.752
Cardiovascular death 1 (1.8) 1 (1.8) 0.752
Stroke/TIA 0 (0.0) 0 (0.0) —
Disabling stroke 0 (0.0) 0 (0.0) —
Nondisabling stroke 0 (0.0) 0 (0.0) —
TIA 1 (1.8) 2 (3.6) 0.537
Permanent PM 6 (10.7) 5 (8.9) 0.799
Bleeding 5 (8.9) 6 (10.7) 0.354
Life threatening 2 (3.6) 0 (0.0) 0.558
Major 1 (1.8) 3 (5.4) 0.309
Minor 2 (3.6) 3 (5.4) 0.647
Hospitalization for heart failure 1 (1.8) 1 (1.8) 0.752
Values are n (%).
PM ¼ pacemaker; TIA ¼ transient ischemic attack.
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1602Length of in-hospital stay (from TAVR to discharge)
was similar in the 2 groups (RenalGuard group 3.5 4.1
days vs. control group 3.5 3.5 days; p¼0.940). VARC-
deﬁned in-hospital outcomes and 30-day outcomes
are listed in Table 4. No signiﬁcant differences in terms
of mortality, cerebrovascular events, bleeding,
vascular complications, and re-hospitalization for
heart failure were noted between groups.
PREDICTORS OF AKI. At the multivariable analysis,
procedures performed without the RenalGuard Sys-
tem (adjusted odds ratio: 5.99, 95% CI: 1.56 to 23.04;
p ¼ 0.009) and AKI risk score 4 (adjusted odds ra-
tio: 4.31, 95% CI: 1.39 to 13.37) were found to be
independently associated with an increased risk
of AKI.DISCUSSION
Baseline renal function should be kept in mind in
elderly and sick patients, such as those with severe
aortic stenosis, because post-operative AKI seems to
signiﬁcantly worsen the early and late prognosis of
those undergoing TAVR (19,21). Despite the wide-
spread utilization of this procedure, no standardized
protocol for AKI prevention has been proposed yet.
The results of this single-center randomized study
powered to detect differences in AKI within 72 h after
TAVR demonstrate that prophylactic intravenous
loading dose of 250-ml normal saline solution com-
bined with furosemide-induced high-volume diuresis
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1603and maintenance of intravascular volume through
automatic matched hydration (RenalGuard system) is
safe and superior to standard infusion of normal sa-
line solution at a high dose.
Hydration remains the cornerstone of AKI
prevention in patients exposed to contrast media
by producing plasma volume expansion with
concomitant suppression of the renin-angiotensin-
aldosterone system, down-regulation of tubuloglo-
merular feedback, dilution of contrast media, and
thus, prevention of renal vasoconstriction and
tubular obstruction (9,10). Furosemide administra-
tion may have some positive effects when associated
with hydration because it enhances contrast dilution
in the renal tubule through increased urine ﬂow and
prevents ﬂuid overload and congestive heart failure.
However, these positive actions may be thwarted by
furosemide-induced reduction of the effective
circulating volume, prostaglandin-mediated venodi-
lation, and dehydration as a result of increased urine
output (22). This explains why achieving a high
urine ﬂow rate is key. In the PRINCE (Prevention of
Radiocontrast Induced Nephropathy Clinical Evalu-
ation) study, a protective effect against contrast-
induced AKI was observed when a mean urine
ﬂow rate >150 ml/h was achieved with a single
dose of diuretic agent and matched intravenous
ﬂuid replacement (23). Hence, there is a rationale
for furosemide-induced high-volume diuresis with
concurrent maintenance of intravascular volume
through matched hydration as an alternative strat-
egy for AKI prevention in high-risk patients.
The RenalGuard System is a device capable of
delivering intravenous ﬂuid in an amount exactly
matched to the volume of urine produced by the
patient and precisely weighed by the system. The
RenalGuard, with its matched ﬂuid replacement
capability, enables the physician to achieve high
urine output safely with a low furosemide dose by
maintaining the intravascular volume and mini-
mizing the risk of overhydration or underhydration.
This feature is important particularly in patients with
severe aortic stenosis, which usually are in labile
hemodynamic compensation.
Two randomized trials (REMEDIAL [Renal Insuf-
ﬁciency After Contrast Media Administration Trial]
and MYTHOS [Induced Diuresis With Matched Hy-
dration Compared to Standard Hydration for
Contrast Induced Nephropathy Prevention]) have
demonstrated that the RenalGuard system protects
patients undergoing percutaneous coronary inter-
vention from AKI (14–16). In the present registry-
based randomized study, we extended these
ﬁndings to a more complex and aged population,where the beneﬁts are expected to accrue. We
showed that the approach of controlled, forced
diuresis with RenalGuard is more effective than
standard hydration protocols in preventing AKI in
patients undergoing TAVR. Indeed, we observed a
79% relative risk reduction in the RenalGuard group
as compared with the control group.
Despite a favorable effect of this strategy, we did
not observe a signiﬁcant reduction in major end-
points (death, bleeding, and so on) in the study
group. This ﬁnding can be explained by the high
prevalence of AKI stage 1, which has been already
demonstrated to not be associated with poorer out-
comes after TAVR (19). Putting these results
into perspective, we can only speculate that a strat-
egy of furosemide-induced diuresis with matched
isotonic intravenous hydration also has the potential
to reduce the risk of AKI stage 2 and 3. To test this
hypothesis, adequately powered studies targeting
patients with AKI stage 2 and 3 are warranted.
Finally, we found that the RenalGuard System
may be well founded in almost all patients undergo-
ing elective TAVR due to its safety proﬁle and its
simple use. In our population, it has been used
without any consequences. Indeed, no hydration-
associated complications were observed, with
only few patients developing asymptomatic hypoka-
lemia that was corrected with potassium supple-
mentation as per usual practice.
STUDY LIMITATIONS. First, this was a single-center
study, which may affect the generalizability of our
ﬁndings. Second, the trial was open-label. Third, the
hydration strategy in the control group did not
include N-acetylcysteine coupled with normal saline
solution. However, the data available on N-ace-
tylcysteine before coronary angiography to prevent
AKI in patients with impaired renal function neither
are conclusive nor provide conclusive proofs to in-
ﬂuence clinical practice and public policies (24).CONCLUSIONS
Furosemide-induced diuresis with matched isotonic
intravenous hydration using the RenalGuard system
is an effective therapeutic tool to reduce the occur-
rence of AKI in patients undergoing TAVR. Larger
studies are warranted to deﬁne the optimal AKI pre-
vention strategy in TAVR patients.
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PERSPECTIVES
WHAT IS KNOWN? Studies conducted in patients
undergoing percutaneous coronary intervention have
recently demonstrated that furosemide-induced diuresis
with matched isotonic intravenous hydration by the
RenalGuard System signiﬁcantly reduced AKI in high-risk
patients undergoing coronary procedures. Whether these
ﬁndings translate to patients undergoing TAVR is
unexplored.
WHAT IS NEW? The results of this single-center ran-
domized study powered to detect differences in AKI
within 72 h after TAVR demonstrate that a prophylactic
intravenous loading dose of 250 ml normal saline solution
combined with furosemide-induced high-volume diuresis
and maintenance of intravascular volume through auto-
matic matched hydration (RenalGuard system) is safe and
superior to standard infusion of normal saline solution at
a high dose.
WHAT IS NEXT? Furosemide-induced diuresis with
matched isotonic intravenous hydration using the
RenalGuard system is an effective therapeutic tool
to reduce the occurrence of AKI in patients undergoing
TAVI.
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